FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: August 10, 2022
New drug candidate fights off more than 300 drug-resistant bacteria
ACS Central Science
Urinary tract infections are common, yet are increasingly tough to treat because the bacteria that cause them are becoming resistant to many antibiotics. Now, in ACS Central Science, researchers report a new molecule that inhibits drug-resistant bacteria in lab experiments, as well as in mice with pneumonia and urinary tract infections. The researchers say that this compound, fabimycin, could one day be used to treat challenging infections in humans.
Gram-negative bacteria are a class of microbes that infect millions of people worldwide, according to the U.S. Centers for Disease Control and Prevention, causing conditions such as pneumonia, urinary tract infections and bloodstream infections. These bacteria are especially difficult to treat because they have strong defense systems 鈥� tough cell walls that keep most antibiotics out and pumps that efficiently remove those antibiotics that get inside. The microbes can also mutate to evade multiple drugs. Furthermore, treatments that do work aren鈥檛 very specific, eradicating many kinds of bacteria, including those that are beneficial. So, Paul Hergenrother and colleagues wanted to design a drug that could infiltrate the defenses of gram-negative bacteria and treat infections, while leaving other helpful microbes intact.
The team started with an antibiotic that was active against gram-positive bacteria and made a series of structural modifications that they believed would allow it to act against gram-negative strains. One of the modified compounds, dubbed fabimycin, proved potent against more than 300 drug-resistant clinical isolates, while remaining relatively inactive toward certain gram-positive pathogens and some typically harmless bacteria that live in or on the human body. In addition, the new molecule reduced the amount of drug-resistant bacteria in mice with pneumonia or urinary tract infections to pre-infection levels or below, performing as well as or better than existing antibiotics at similar doses. The researchers say the results show that fabimycin could one day be an effective treatment for stubborn infections.
The authors acknowledge funding from the University of Illinois, the National Institutes of Health, the National Science Foundation, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, Anita and Josh Bekenstein, Biomedical Advanced Research and Development Authority, Military Infectious Diseases Research Program and the Roy J. Carver Charitable Trust.
###
The American Chemical 中国365bet中文官网 (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The 中国365bet中文官网 is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical聽Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world鈥檚 scientific knowledge. ACS鈥� main offices are in Washington, D.C., and Columbus, Ohio.
Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.
Media Contact
ACS Newsroom
newsroom@acs.org
###
La sociedad American Chemical 中国365bet中文官网 (ACS) es una organizaci贸n sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformaci贸n del poder de la qu铆mica. Su misi贸n es promover el conocimiento cient铆fico, empoderar a la comunidad global y defender la integridad cient铆fica, y su visi贸n es un mundo construido bas谩ndose en la ciencia. La Sociedad es l铆der mundial en la promoci贸n de la excelencia en la educaci贸n cient铆fica y en el acceso a informaci贸n e investigaci贸n relacionadas con la qu铆mica a trav茅s de sus m煤ltiples soluciones de investigaci贸n, publicaciones revisadas por expertos, conferencias cient铆ficas, libros electr贸nicos y noticias semanales peri贸dicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las m谩s citadas, las m谩s fiables y las m谩s le铆das en la literatura cient铆fica; sin embargo, la propia ACS no realiza investigaci贸n qu铆mica. Como l铆der en soluciones de informaci贸n cient铆fica, su divisi贸n CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservaci贸n, la conexi贸n y el an谩lisis de los conocimientos cient铆ficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.
Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa p煤blicos y retenidos.聽 Para consultas de los medios, comun铆quese con newsroom@acs.org.
Nota: ACS no realiza investigaciones, pero publica y divulga estudios cient铆ficos revisados por expertos.鈥�
Correction
Correction
**A to the journal article was published on Sept. 6, 2022**
;void(0);){kind=link}